Patents Assigned to ZymoGenetics
  • Human serpin
    Patent number: 7064182
    Abstract: Members of the serine protease family play a role in carefully controlled processes, such as blood coagulation, fibrinolysis, complement activation, fertilization, and hormone production. The enzymatic activity of the serine proteases is regulated in part by serpins, serine protease inhibitors. Serpin dysfunction is associated with various disorders, including emphysema, blood clotting disorders, cirrhosis, Alzheimer disease, and Parkinson disease. Zserp11 is a new member of the serine protease inhibitor family.
    Type: Grant
    Filed: August 7, 2002
    Date of Patent: June 20, 2006
    Assignee: ZymoGenetics, Inc.
    Inventor: James L. Holloway
  • Protection against ischemia and reperfusion injury
    Patent number: 7060792
    Abstract: A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound, either Deltorphin A and/or Dermorphin H, may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: June 13, 2006
    Assignees: University of Kentucky Research Foundation, Zymogenetics
    Inventors: Peter R. Oeltgen, Paul D. Bishop, Mark S. Kindy, Juan A. Sanchez
  • Human serine protease
    Patent number: 7049126
    Abstract: Members of the serine protease family play a role in carefully controlled processes, such as blood coagulation, fibrinolysis, complement activation, fertilization, and hormone production. These enzymes are also used in a variety of diagnostic, therapeutic, and industrial contexts. Ztryp3 is a new member of the serine protease family.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: May 23, 2006
    Assignee: ZymoGenetics, Inc.
    Inventor: Darrell C. Conklin
  • Method for treating inflammatory bowel disease
    Publication number: 20060104946
    Abstract: A method for treating inflammatory bowel disease by administering interferon beta in conjunction with factor XIII to a mammal afflicted with the disease. The IBD may either be ulcerative colitis or Crohn's disease. The factor XIII used may be recombinant or nonrecombinant. The interferon beta used can be naturally occurring interferon beta, interferon beta-1a or interferon beta-1b.
    Type: Application
    Filed: August 25, 2003
    Publication date: May 18, 2006
    Applicant: ZYMOGENETICS, INC.
    Inventor: Jan Ohrstrom
  • Soluble Zcytor11 cytokine receptors
    Patent number: 7045498
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: May 16, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne R. Kindsvogel, Stavros Topouzis
  • Cytokine protein family
    Patent number: 7038032
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: May 2, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Brian A. Fox, Kevin M. Klucher, David W. Taft, Wayne Kindsvogel
  • Blood coagulation factor XIII for treating platelet disorders
    Patent number: 7008926
    Abstract: Use of factor XIII for treating the symptoms of thrombocytopenia. A patient having thrombocytopenia, either chemically- or metabolically induced, is treated by administering factor XIII.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: March 7, 2006
    Assignee: ZymoGenetics Inc.
    Inventor: Paul D. Bishop
  • Adipocyte complement related protein homolog zacrp7
    Publication number: 20060040360
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp7, a novel member of the family of proteins bearing a collagen-like domain and a Clq domain. The polypeptides and polynucleotides encoding them, are involved in homo and heterotrimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zacrp7 polypeptides.
    Type: Application
    Filed: October 25, 2005
    Publication date: February 23, 2006
    Applicant: ZymoGenetics, Inc.
    Inventors: Christopher Piddington, Paul Sheppard
  • Method for treating von willebrand's disease
    Patent number: 6979445
    Abstract: Use of factor XIII for treating von Willebrand's disease. A patient having von Willebrand's disease is treated by administering factor XIII generally in conjunction with factor VIII concentrate, 1-desamino-8-D-arginine vasopressin (DDAVP) or desmopressin.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: December 27, 2005
    Assignee: Zymogenetics, INC
    Inventor: Paul D. Bishop
  • Growth factor homolog ZVEGF4
    Patent number: 6962802
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: November 8, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Teresa Gilbert, Charles E. Hart, Paul O. Sheppard, Debra G. Gilbertson
  • Adipocyte complement related protein zacrp13
    Patent number: 6955899
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp13, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp13 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp13 protein or fragments thereof.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: October 18, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Brian A. Fox, James L. Holloway
  • Pichia methanolica secretory signal
    Patent number: 6943234
    Abstract: Novel Pichia methanolica secretory signal polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods of using are disclosed. Methods of producing large amounts of recombinant proteins by employing DNA constructs having a polypeptide of interest preceded by a novel Pichia methanolica secretory signal sequence.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: September 13, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Christopher K. Raymond, Michael R. Stamm
  • Polynucleotides encoding motilin homologs
    Patent number: 6939690
    Abstract: The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: September 6, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Theresa A. Deisher, Paul D. Bishop, Stephen R. Jaspers, Virender M. Labroo
  • IL-21 antagonists
    Patent number: 6929932
    Abstract: The polypeptides, and the polynucleotides encoding for them, described herein are IL-21 antagonists that bind with specificity and exhibit an EC50 that is not detectable in receptor binding studies. These molecules have mutations in the D helix of the IL-21 molecule, and can be used to inhibit the activity of IL-21 with its cognate receptor.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: August 16, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, James W. West, Julia E. Novak
  • Interferon-like protein Zcyto21
    Patent number: 6927040
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: August 9, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant
  • Human secreted protein, Zzp1
    Patent number: 6924364
    Abstract: The present invention relates to polynucleotide and polypeptide molecules, and variants thereof, for Zzp1, a novel Zona Pellucida protein. The polypeptides, and polynucleotides encoding them, are fertility modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the Zzp1 polypeptides.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: August 2, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Edward C. Thayer, Philippa J. Webster
  • Method for treating cytokine mediated hepatic injury
    Publication number: 20050164942
    Abstract: A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.
    Type: Application
    Filed: March 22, 2005
    Publication date: July 28, 2005
    Applicants: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, ZymoGenetics
    Inventors: Peter Oeltgen, Paul Bishop, Craig McClain, Shirish Barve
  • Polynucleotide encoding adipocyte complement related protein homolog zacrp2
    Patent number: 6921649
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp2, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. The polypeptides and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zacrp2 polypeptides.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: July 26, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Christopher S. Piddington, Paul D. Bishop
  • Proteinase inhibitor ZSERP9
    Patent number: 6921807
    Abstract: A novel proteinase inhibitor and materials and methods for making it are disclosed. The proteinase inhibitor comprises residues 3-425 of SEQ ID NO:2. The proteinase inhibitor may be used as components of cell culture media, in protein purification, and in certain therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: July 26, 2005
    Assignee: ZymoGenetics, Inc.
    Inventor: James L. Holloway
  • Method for inhibiting the formation of seromas using factor XIII
    Publication number: 20050159338
    Abstract: Use of factor XIII for inhibiting the formation of seromas by administering factor XIII. The factor XIII can be administered locally at the site of a wound or surgery or administered systemically. If the factor XIII is administered locally, it can be activated or non-activated and may be administered in conjunction with activated thrombin.
    Type: Application
    Filed: March 16, 2005
    Publication date: July 21, 2005
    Applicant: Zymogenetics, Inc.
    Inventors: Paul Bishop, Angelika Grossmann